Why is the use of clopidogrel increasing rapidly in Australia? An exploration of geographical location, age, sex and cardiac stenting rates as possible influences on clopidogrel use

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 11, 2008, Pages 1077-1090

  Ostini, R ^a   Hegney, D ^a   Mackson, J M ^b   Williamson, M ^b   Tett, S E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b National Prescribing Service   (Australia)

Author keywords

Clopidogrel; Prescribing influences; Remote area; Utilisation

Indexed keywords

CLOPIDOGREL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DRUG INDICATION; DRUG MARKETING; DRUG UTILIZATION; FEMALE; GEOGRAPHIC DISTRIBUTION; HEART SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; STENT; URBAN RURAL DIFFERENCE; VETERAN;

AGE FACTORS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; AUSTRALIA; DRUG UTILIZATION; FEMALE; HUMANS; LINEAR MODELS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; RESIDENCE CHARACTERISTICS; SEX FACTORS; STENTS; TICLOPIDINE; TIME FACTORS; URBAN HEALTH SERVICES;

EID: 57649186589     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1638     Document Type: Article

References (40)

1. Behan K, Cutts C, Tett SE. Motivations and perceived influences on rural and urban general practitioners when prescribing conventional non-steroidal anti-inflammatory drugs or COX-2 inhibitors. J Clin Pharm Ther 2005; 30(4): 337-343.
2. Cutts C, Tett SE. Doctors perceptions of the influences on their prescribing: a comparison of general practitioners based in rural and urban Australia. Eur J Clin Pharmacol 2003; 58(11): 761-766.
3. Davis DA, TaylorVaisey A. Translating guidelines into practice - a systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. Can Med Assoc J 1997; 157(4): 408-416.
4. Davis PB, Yee RL. The influence of practitioner and practice characteristics on service activity levels in a New Zealand general practice sample. Community Health Stud 1989; 13(2): 191-199.
5. Gallan AS. Factors that influence physicians' prescribing of pharmaceuticals: a literature review. J Pharm Mark Manage 2004; 16(4): 3-46.
6. Grindrod KA, Patel P, Martin JE. What interventions should pharmacists employ to impact health practitioners' prescribing practices? Ann Pharmacother 2006; 40(9): 1546-1557.
7. Groves KEM, Fanagan PS, MacKinnon NJ. Why physicians start or stop prescribing a drug: literature review and formulary implications. Formulary 2002; 37(4): 186-194.
8. Haynes RB, Devereaux PJ, Guyatt GH. Physicians' and patients' choices in evidence based practice. Br Med J 2002; 324(7350): 1350.
9. Sansom L. The subsidy of pharmaceuticals in Australia: processes and challenges. Aust Health Rev 2004; 28(2): 194-1205.
10. Chow G, Ziegelstein RC. Clopidogrel: the good, the bad, and the ugly. Am J Cardiovasc Drugs 2007; 7(3): 169-171.
11. Emmons KL, Taylor NR. Contemporary issues in clopidogrel therapy: new evidence shaping clinical practice. Pharmacotherapy 2007; 27(4): 553-563.
12. Eshaghian S, Kaul S, Amin S, Shah PK, Diamond GA. Role of clopidogrel in managing atherothrombotic cardiovascular disease. Ann Intern Med 2007; 146(6): 434-441.
13. Galla JM, Lincoff AM. The role of clopidogrel in the management of ischemic heart disease. Curr Opin Cardiol 2007; 22(4): 273-279.
14. Keller T, Squizzato A, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev 2007; (3): CD005158.
15. Plosker GL, Lyseng-Williamson KA. Clopidogrel: a review of its use in the prevention of thrombosis. Drugs 2007; 67(4): 613-646.
16. Cheng JW. Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease. J Manag Care Pharm 2007; 13(4): 326-336.
17. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366(9497): 1607-1621.
18. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7): 494-502.
19. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294(10): 1224-1232.
20. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348(9038): 1329-1339.
21. Brener SJ, Steinhubl SR, Berger PB, Brennan DM, Topol EJ. Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial. J Invasive Cardiol 2007; 19(7): 287-290.
22. Australian Department of Health and Ageing. Expenditure and Prescriptions Twelve Months to 30 June 2007, 2007.
23. Simpson CR, Alford K, Williams D. Evidence for prolonged prescribing of aspirin-clopidogrel combination in Scottish primary care. Pharmacoepidemiol Drug Saf 2008; 17(4): 397-400.
24. Main C, Palmer S, Griffin S, et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess 2004; 8(40): iii-iv, xv-xvi, 1-141.
25. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354(16): 1706-1717.
26. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364(9431): 331-337.
27. Australian Adverse Drug Reactions Advisory Committee. Clopidogrel - haemorrhage and haematological disorders. Aust Adverse Drug React Bull 2004; 23(4): 14-15.
28. Antoniou S, Rothman MT. Stent thrombosis: patient card on discontinuing clopidogrel is available. Br Med J 2007; 334(7584): 57.
29. Senes S, Penm E. Medicines for Cardiovascular Health: Are They Used Appropriately. Australian Institute for Health and Welfare: Canberra, 2007.
30. Grimshaw JM, Eccles MP, Walker AE, Thomas RE. Changing physicians' behavior: what works and thoughts on getting more things to work. J Contin Educ Health Prof 2002; 22(4): 237-243.
31. Australian Institute for Health and Welfare. Rural, Regional and Remote Health: A Guide to Remoteness Classifications. Australian Institute of Health and Welfare: Canberra, 2004.
32. National Social Health Database Project. HealthWIZ 7.3.4. Prometheus: Canberra, 2005.
33. Chan V, Tett SE. How is leflunomide prescribed and used in Australia? Analysis of prescribing and adverse effect reporting. Pharmacoepidemiol Drug Saf 2006; 15(7): 485-493.
34. Wang TH, Bhatt DL, Fox KA, et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J 2007; 28(18): 2200-2207.
35. Queensland Health. Standard Drug List. Queensland Health: Brisbane, 2007.
36. Park SJ, LeeSW. Optimal management of platelet function after coronary stenting. Curr Treat Options Cardiovasc Med 2007; 9(1): 37-45.
37. Bernardi V, Szarfer J, Summay G, et al. Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] trial). Am J Cardiol 2007; 99(3): 349-352.
38. Australian Institute for Health and Welfare. Australia's Health, Canberra, 2006.
39. Australian Institute for Health and Welfare. Rural, Regional and Remote Health: Indicators of Health Status and Determinants of Health. Canberra, 2008.
40. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299(5): 532-539.